Brief: Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement

ONO PHARMACEUTICAL

18/07/2019 11:39

July 18 (Reuters) - Ono Pharmaceutical Co Ltd  4528.T :
    * BAYER, BRISTOL-MYERS SQUIBB AND ONO PHARMACEUTICAL ENTER
INTO A
CLINICAL COLLABORATION AGREEMENT TO INVESTIGATE STIVARGA®
(REGORAFENIB) AND OPDIVO® (NIVOLUMAB) AS COMBINATION THERAPY IN
PATIENTS WITH METASTATIC COLORECTAL CANCER
    * BRISTOL-MYERS SQUIBB CO - COMPANIES PLAN
INDICATION-SEEKING
TRIAL
    * BRISTOL-MYERS SQUIBB CO - FURTHER TERMS OF CLINICAL
COLLABORATION WERE NOT DISCLOSED.
    * BRISTOL-MYERS - COMBINATION OF REGORAFENIB, NIVOLUMAB
VERSUS.
REGORAFENIB TO BE EVALUATED IN PATIENTS WITH MICRO-SATELLITE
METASTATIC COLORECTAL CANCER
    * BRISTOL-MYERS - DATA SEEN IN REGONIVO WARRANT FURTHER
EXPLORATION OF COMBINATION OF REGORAFENIB AND NIVOLUMAB IN
PATIENTS WITH COLORECTAL CANCER

Source text for Eikon:  ID:nBw66rZ5pa 
Further company coverage:  4528.T 

 ((Reuters.Briefs@thomsonreuters.com;))